Pravin U. Dugel
- Ophthalmology top 0.02%
- Retinal Diseases and Treatments 86
- Glaucoma and retinal disorders 33
- Retinal and Optic Conditions 33
- Intraocular Surgery and Lenses 29
- Ocular Diseases and Behçet’s Syndrome 23
-
- Retinal Imaging and Analysis 47
- Retinal and Macular Surgery 42
- Neurology top 2%
- Vascular Malformations Diagnosis and Treatment 16
- Microbiology top 5%
- Molecular Biology top 5%
- Co-authors
- Jack O. SipperleyScott R. SneedFrank G. HolzGlenn J. JaffeDonald W. ParkAdrian KohAndreas WeichselbergerJames Warburton
- Partner nations
- United StatesSwitzerlandUnited Kingdom
In The Last Decade
Pravin U. Dugel
148 papers receiving 6.8k citations
Hit Papers
Peers
Comparison fields: 5 of 116
- Ophthalmology 6.3k
- Radiology, Nuclear Medicine and Imaging 4.4k
- Neurology 645
- Microbiology 16
- Molecular Biology 1.4k
Countries citing papers authored by Pravin U. Dugel
This map shows the geographic impact of Pravin U. Dugel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pravin U. Dugel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pravin U. Dugel more than expected).
Fields of papers citing papers by Pravin U. Dugel
This network shows the impact of papers produced by Pravin U. Dugel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pravin U. Dugel. The network helps show where Pravin U. Dugel may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Pravin U. Dugel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 32 | |
| 2 | HAWK and HARRIERbreakdown → | 2020 | 260 |
| 3 | Assessing the Efficacy and Safety of Intravitreal Dexamethazone Implant in Treating Macular Edema in Eyes with an Incomplete Response to Anti-vascular Endothelial Growth Factor Agents. | 2019 | 1 |
| 4 | 2019 | 179 | |
| 5 | Predictability of the 12-week dosing status at Week 48 for patients receiving brolucizumab in HAWK and HARRIER | 2018 | 2 |
| 6 | Quantitative assessment of changes in retinal vascular density and morphology among patients with diabetic retinopathy using spectral domain optical coherence tomography angiography (SD-OCTA) | 2018 | 2 |
| 7 | No Clear Benefit of Vitrectomy for Post-Injection Endophthalmitis in Age-Related Macular Degeneration | 2017 | 1 |
| 8 | 3-Year Interim Safety Profile of Adeno-Associated Virus Serotype 2-soluble Variant of the Vascular Endothelial Growth Factor Receptor Type 1 (AAV2-sFLT01) Administered by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration | 2017 | 2 |
| 9 | Quantitative spectral-domain optical coherence tomography angiography (OCTA) of Diabetic Retinopathy (DR) Severity | 2017 | 2 |
| 10 | Comorbidity and Healthcare Visit Burden in Elderly Diabetic Macular Edema Patients | 2015 | 3 |
| 11 | Treatment Patterns and Associated Costs of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration | 2014 | 2 |
| 12 | Safety profile of ocriplasmin for symptomatic vitreomacular adhesion - a comprehensive analysis of pre- and post-marketing experiences | 2014 | 2 |
| 13 | A Phase I single ascending dose study of an intravitreal (IVT) anti-C5 monoclonal antibody (LFG316) in patients with advanced age related macular degeneration (AMD) | 2014 | 5 |
| 14 | Voclosporin for Noninfectious Uveitis Involving the Posterior Segment: New Analyses of the LUMINATE Phase 2/3 Trials | 2012 | 1 |
| 15 | 2011 | 27 | |
| 16 | A Single Injection Of Ocriplasmin For The Treatment Of Symptomatic Vitreomacular Adhesion (sVMA): Results Of The Phase III MIVI-TRUST Program | 2011 | 2 |
| 17 | A Multicenter, Randomized, Double-Masked, Dose-Ranging, Placebo-Controlled Phase 2 Study to Assess Sirolimus in the Treatment of Patients With Diabetic Macular Edema (DIAMOND Study) | 2010 | 1 |
| 18 | 2010 | 13 | |
| 19 | Efficacy and Safety of a Novel Intravitreous Dexamethasone Drug–Delivery System After Applicator or Incisional Placement in Patients With Macular Edema | 2006 | 4 |
| 20 | 2001 | 29 |
About Pravin U. Dugel
Pravin U. Dugel is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Neurology, having authored 151 papers that have together received 7.1k indexed citations. Recurring topics across this work include Retinal Diseases and Treatments (86 papers), Retinal Imaging and Analysis (47 papers), Retinal and Macular Surgery (42 papers), Glaucoma and retinal disorders (33 papers), Retinal and Optic Conditions (33 papers), Intraocular Surgery and Lenses (29 papers), Ocular Diseases and Behçet’s Syndrome (23 papers) and Vascular Malformations Diagnosis and Treatment (16 papers). The work is most often cited by research in Ophthalmology (6.3k citations), Radiology, Nuclear Medicine and Imaging (4.4k citations) and Neurology (645 citations). Pravin U. Dugel has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Jack O. Sipperley, Scott R. Sneed, Frank G. Holz, Glenn J. Jaffe, Donald W. Park, Adrian Koh, Andreas Weichselberger, James Warburton, Yuichiro Ogura and Ursula Schmidt‐Erfurth. Their work appears in journals such as Ophthalmology, Retina, American Journal of Ophthalmology, Investigative Ophthalmology & Visual Science and Clinical ophthalmology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.